...
首页> 外文期刊>Journal of Biomolecular Structure and Dynamics >Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative in silico and molecular modeling approach
【24h】

Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative in silico and molecular modeling approach

机译:识别含有N-甲基-D-天冬氨酸受体抑制剂的潜在GLUN2B亚基:硅和分子建模方法中的一体化

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

N-methyl-D-aspartate receptors (NMDARs), a class of ligand-gated ion channels, are involved in non-selective cation transport across the membrane. These are contained in glutamatergic synapse and produce excitatory effects leading to synaptic plasticity and memory function. GluN1-GluN2B, a subtype of NMDAR(s), has significant role in neurodegeneration, amyloid beta (A beta) induced synaptic dysfunction and loss. Thus, targeting and inhibiting GluN1-GluN2B may be effective in the management of neurodegenerative diseases including Alzheimer's disease. In the present study, ligand and structure-based approaches were tried to identify the inhibitors. The pharmacophore, developed from co-crystallised ifenprodil, afforded virtual hits, which were further subjected through drug likeliness and PAINS filters to remove interfering compounds. Further comprehensive docking studies, free energy calculations and ADMET studies resulted in two virtual leads. The leads, ZINC257261614 and ZINC95977857 displayed good docking scores of -12.90 and -12.20 Kcal/mol and free binding energies of -60.83 and -61.83 Kcal/mol, respectively. The compounds were having acceptable predicted ADMET profiles and were subjected to molecular dynamic (MD) studies. The MD simulation produced stable complexes of these ligands with GluN1-GluN2B subunit having protein and ligand RMSD in acceptable limit.
机译:N-甲基-D-天冬氨酸受体(NMDARS),一类配体门通道,涉及穿过膜的非选择性阳离子输送。这些包含在谷氨酸突变突触中,并产生兴奋的效果,导致突触可塑性和记忆功能。 Glun1-Glun2b是NMDAR的亚型,在神经变性中具有显着作用,淀粉样蛋白β(Aβ)诱导突触功能障碍和损失。因此,靶向和抑制Glun1-Glun2B可以有效地管理包括阿尔茨海默病的神经变性疾病。在本研究中,试图鉴定抑制剂的配体和基于结构的方法。从共结晶的Ifenprodil中发育的药效线,得到虚拟命中,通过药物可能性进一步进行,以除去干涉化合物。进一步的综合对接研究,自由能量计算和备用探险研究导致了两个虚拟领导。引线,ZINC257261614和ZINC95977857显示出-12.90和-12.20千卡/摩尔/摩尔和-60.83和-61.83 kcal / mol的自由结合能量的良好对接。该化合物具有可接受的预测备注谱,并进行分子动态(MD)研究。 MD模拟在可接受的极限中产生具有蛋白质和配体RMSD的GLUN1-GLUN2B亚基的这些配体的稳定复合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号